Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMB-100 + Ipilimumab in Malignant Mesothelioma
NCT04840615Phase 1Terminated
- Sponsor
- National Cancer Institute
- Start
- Jun 2021
- Primary completion
- Dec 2021
- Modality
- Antibody-Drug Conjugates (ADCs), Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LMB-100 in malignant mesothelioma, sponsored by National Cancer Institute. Primary endpoints: Recommended Phase 2 Dose at 21 days, Toxicity Related to LMB-100 at 3.4 months and 1 more. Started Jun 2021; status: terminated.
02
Drugs
LMB-100
03
Conditions
malignant mesothelioma
Beyond the preview
Go deeper on NCT04840615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04840615.